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ABSTRACT: 24 
Background: Cough in asthma is a common and troublesome symptom. It is generally 25 
assumed coughing occurs as a consequence of bronchial hyper-responsiveness and 26 
inflammation, but the possibility that airway nerves are dysfunctional has not been fully 27 
explored. 28 
Objectives: To investigate capsaicin evoked cough responses in a group of well-29 
characterised mild to moderate asthma patients compared with healthy volunteers, and 30 
assess the influences of gender, atopy, lung physiology, inflammation and asthma control on 31 
these responses.  32 
Methods: Capsaicin inhalational challenge was performed and cough responses analysed 33 
using non-linear mixed effects modelling to estimate maximal cough responses (Emax) and 34 
the dose evoking half this response (ED50). 35 
Results: Ninety-seven stable asthmatics (median age 23yrs (IQR 21-27), 60% female) and 47 36 
healthy volunteers (38yrs (29-47), 64% female) were recruited. Asthmatics had a higher Emax 37 
and lower ED50 than healthy volunteers. Emax was 27% higher in females (p=0.006), 46% 38 
higher in non-atopic asthma (p=0.003) compared with healthy volunteers. Also, atopic 39 
asthmatics had a 21% lower Emax than non-atopic asthmatics (p=0.04). ED50 was 65% lower 40 
in females (p=0.0001) and 71% lower in all asthmatics (p=0.0008). ED50 was also influenced 41 
by asthma control and serum IgE, whilst Emax was related to 24hr cough frequency. Age, 42 
BMI, FEV1, PC20, FeNO, blood eosinophils and inhaled steroid treatment did not influence 43 
cough parameters.  44 
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Conclusion: Stable asthmatics exhibited exaggerated capsaicin cough responses consistent 45 
with neuronal dysfunction. Non-atopic asthmatics had the highest cough responses, 46 
suggesting this mechanism may be most important in type 2-low asthma phenotypes. 47 
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KEY MESSAGES 48 
• Using a novel challenge methodology and pharmacodynamic modelling we have 49 
demonstrated that mild/moderate subjects with asthma have a heightened cough 50 
response to inhaled capsaicin, most evident in female non-atopic subjects. 51 
• Unlike standard cough challenge endpoints (C2 and C5), the capsaicin Emax and 52 
ED50 were influenced by gender, spontaneous cough frequency, asthma control and 53 
measures of atopy (IgE and Skin prick testing).  54 
 55 
CAPSULE SUMMARY 56 
This study shows that performing non-linear modelling of cough responses to full dose 57 
capsaicin challenges discriminates healthy volunteers from subjects with mild/moderate 58 
asthma, and reveals novel relationships between cough responses, atopy and asthma 59 
control. 60 
  61 
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Key words: atopy; transient receptor potential vanilloid type 1; vagus; pharmacodynamic 62 
modelling  63 
  64 
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ABBREVIATIONS USED: 65 
ACQ, Asthma control questionnaire, BDNF, Brain-derived natriuretic factor; BHR, Bronchial 66 
hyper-responsiveness; BMI, Body mass index; C2, Concentration of capsaicin inducing at 67 
least 2 coughs; C5, Concentration of capsaicin inducing at least 5 coughs; ED50, Capsaicin 68 
dose inducing half-maximal response; Emax, Maximum cough response evoked by any 69 
concentration of capsaicin; FENO, Fractional exhaled nitric oxide; FEV1, Forced expiratory 70 
volume in 1 second; FVC, Forced vital capacity; GINA, Global initiative for Asthma; HV, 71 
Healthy volunteers; LCQ, Leicester cough questionnaire; NGF, Nerve growth factor; PC20, 72 
Provocative concentration of methacholine causing a 20% drop in FEV1; TRPV1, Transient 73 
receptor potential vanilloid type 1 74 
  75 
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INTRODUCTION 76 
Asthma affects an estimated 300 million people worldwide, and is characterised by 77 
symptoms of cough, wheeze, chest tightness and shortness of breath. Current dogma 78 
suggests asthma symptoms arise as a consequence of airway narrowing, bronchial hyper-79 
responsiveness (BHR) and airway inflammation. Yet despite effective treatments targeting 80 
each of these components of asthma, many patients have substantial residual symptoms.  81 
Even in a clinical trial setting, with optimal inhaled treatment, up to 50% of asthma patients 82 
are not well controlled
1
. Whilst for some patients adherence might be an issue
2
 it is also 83 
likely that undiscovered mechanisms explain the heterogeneity in asthma clinical 84 
phenotypes and treatment responses.  85 
Symptoms are often challenging to study as they can only be reported subjectively; cough 86 
however, is readily amenable to objective quantification3. Cough in asthma is not only a 87 
common
4
 and troublesome symptom
5
, but also predicts disease severity 
6
 and poor 88 
prognosis
7
, suggesting it reflects important pathophysiological processes, yet remarkably 89 
little is understood about the underlying mechanisms. The general assumption is that airway 90 
afferent nerves activating the cough reflex are stimulated by inflammatory mediators, 91 
mucous and bronchospasm, and the possibility that these neuronal pathways are 92 
dysfunctional is rarely considered.  93 
Vagal afferent fibres innervate the airways and are responsible for mediating symptoms and 94 
airway reflexes
8, 9
. Coughing is readily evoked by activation of C fibres; these networks of 95 
un-myelinated chemically sensitive afferents are characteristically sensitive to capsaicin 96 
(chilli pepper extract) through activation of the transient receptor potential vanilloid type 1 97 
(TRPV1) channel. Aδ fibres are sparsely distributed thinly myelinated fibres in the proximal 98 
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airways and also evoke cough. They protect the airways by responding to mechanical stimuli 99 
(e.g. foreign objects), and changes in osmolarity and acidity. Importantly, they are typically 100 
insensitive to capsaicin and inflammatory mediators and do not usually express TRPV1. 101 
Experimentally evoked cough responses to inhaled irritants are an established tool for 102 
studying the cough reflex, and thus airway nerve function. Capsaicin is the most widely used 103 
agent and the concentration causing ≥5 coughs (C5) considered a measure of cough reflex 104 
sensitivity 
3
. However, previous studies in asthma have produced conflicting results, with 105 
some studies suggesting sensitisation of the cough reflex (reduced C5), whilst others found 106 
no difference from healthy controls
10-12, 19
. We have recently investigated capsaicin evoked 107 
cough responses using repeat inhalations of capsaicin and concentrations beyond the C5. 108 
Non-linear mixed effects modelling of this data found maximal cough responses (Emax) best 109 
discriminated patients with chronic cough from healthy controls/mild asthma subjects; the 110 
difference between healthy and asthma subjects did not quite reach the a priori statistical 111 
significance
15
. Therefore, we have studied capsaicin evoked cough responses in a larger 112 
group of well-characterised mild to moderate asthma patients and healthy volunteers. We 113 
also investigated the influences of gender, atopic status, lung physiology, inflammation and 114 
asthma control on capsaicin cough responses. Some of the results of these studies have 115 
been previously reported in the form an abstract
13, 14
. 116 
 117 
METHODS: 118 
Subjects: Subjects with a physician diagnosis of asthma were recruited, but not selected for 119 
symptoms of cough. Treatment with salbutamol as required, and/or inhaled corticosteroid 120 
(ICS) ≤500mcg of fluticasone propionate equivalent daily, with or without a long acting 121 
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bronchodilator (LABA) was permitted. Subjects uncontrolled according to Global Initiative 122 
for Asthma (GINA) classification or not on stable medication over the previous four weeks 123 
were excluded. Healthy controls, approximately matched for age were also recruited. We 124 
excluded current smokers, those with a recent chest infection or exacerbation, and use of 125 
any medication which may alter the cough responses (e.g. opiates, gabapentin, anti-126 
cholinergics, and theophylline). The study protocols for healthy controls and subjects with 127 
asthma were approved by the local research ethics committee (13/COA/002 and 128 
13/CLU/001) and all subjects provided written informed consent. 129 
Study Protocol and Procedures: For full details see the online repository. Subjects with 130 
asthma attended on three occasions. On visit 1, subjects underwent history and 131 
examination, completed the Asthma Control Questionnaire (ACQ), Leicester Cough 132 
Questionnaire (LCQ), exhaled breath nitric oxide (FeNO) (NIOX, Aerocrine), spirometry, 133 
bronchodilator reversibility and an ambulatory cough monitor (VitaloJAK™; Vitalograph, 134 
Buckinghamshire, UK) was fitted for the next 24 hours. At Visit 2, at least 48 hours later, 135 
subjects underwent full blood count, serum IgE, skin prick testing, and the provocative 136 
concentration of methacholine challenge causing a 20% drop in FEV1 (PC20). Subjects 137 
completed a peak flow diary twice a day for 7 days after visit 2. 138 
Visit 3 took place at least one week later and a capsaicin cough challenge was performed as 139 
previously described
15
, using a dosimeter (Koko Dosimeter; Ferraris Ltd, Hertford, UK) and a 140 
nebuliser pot (Model 646; Devilbiss Healthcare LLC) with an inspiratory flow limiter. Briefly, 141 
four inhalations were administered, thirty seconds apart, of doubling doses of capsaicin 142 
(0.48-1000µmol/L). After each inhalation, the number of coughs in the first 15 seconds was 143 
counted and later verified using a cough monitor (VitaloJAK™). The challenge was 144 
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completed when the patient reached the final dose or the maximal tolerated dose. 145 
Spirometry was performed before and after each challenge. 146 
Healthy volunteers attended on two occasions. On visit 1 consent, screening, spirometry, 147 
and the ambulatory cough monitor was attached. On visit 2, the capsaicin challenge was 148 
performed. 149 
Statistical Analysis: Cough responses to capsaicin were analysed using nonlinear mixed 150 
effects modelling software (NONMEM
®
 7.3, ICON Development Solutions) and the Laplace 151 
estimation method
16, 17
. Additional investigations of the NONMEM output, statistical and 152 
graphical analyses were performed in Matlab R2014a (The MathWorks, Inc., Natick, MA). 153 
We applied a modelling approach developed previously
15
; the number of coughs was 154 
assumed to follow a Poisson distribution, adjusted for tachyphylaxis evoked by repeat 155 
inhalations of the same capsaicin dose. The capsaicin cough response curve was assumed to 156 
follow a sigmoid shape where the maximum response was denoted Emax and the dose 157 
evoking half this response ED50.The effect of continuous and categorical covariates were 158 
investigated including: age, gender, body mass index, disease state (healthy or asthmatic), 159 
atopy (atopic or non-atopic), predicted FEV1, cough frequency, serum IgE, blood eosinophil 160 
count, FeNO, methacholine PC20, ACQ, and LCQ questionnaires. The pharmacodynamic 161 
model was used to simulate typical dose response curves for significant covariates. Finally, 162 
we also calculated the traditional C2 and C5 endpoints from our challenges to explore the 163 
differences between healthy controls and subjects with asthma, and the effects of the same 164 
continuous and categorical covariates. See the online repository for full details of the non-165 
linear model and C2/C5 analyses. 166 
 167 
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RESULTS: 168 
Subjects 169 
Ninety-seven subjects with asthma and 47 healthy volunteers were recruited and completed 170 
all visits; see online repository Figure E1 for exclusions, withdrawals and missing data. 171 
Asthma patients and healthy volunteers were well matched for gender, body mass index 172 
(BMI) and smoking history, but asthmatic subjects were significantly younger and had 173 
slightly reduced lung volumes compared with healthy volunteers (Table 1). Asthmatic 174 
subjects had low cough frequencies but these were statistically higher than healthy 175 
volunteers.  176 
Asthma subjects were well or partly controlled (Table 2). Almost 50% were steroid naïve and 177 
one third on a low dose of inhaled steroid. The majority were atopic based on ≥1 positive 178 
skin prick test to a common aero-allergen, and exhibited bronchial hyper-responsiveness to 179 
methacholine.  180 
Application of pharmacodynamic model 181 
The model parameters are described in Table 3, and Figure E2 shows a very good fit of the 182 
model to the observed raw capsaicin evoked cough data. The model fit was also accurate at 183 
the individual level (see Figure E3). The subject characteristics that significantly affected Emax 184 
and ED50 are also summarised in Table 3.  185 
Asthma, gender, and atopic status significantly affect capsaicin cough responses 186 
Asthmatic subjects (both atopic and non-atopic) had a higher Emax and lower ED50 compared 187 
with healthy volunteers (Tables 3, 4 and Figure 1a). Specifically, asthmatics had a 71% lower 188 
ED50 (p=0.0008) than healthy volunteers, with no difference in ED50 between atopic and 189 
non-atopic asthma subjects. Non-atopic asthmatics had a 46% higher Emax (p=0.003) 190 
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compared with healthy volunteers but atopic asthmatics had a 21% lower Emax (p=0.04) 191 
than non-atopic asthmatics (Tables 3, 4 and Figure 1c). In addition, female gender increased 192 
Emax by 27% (p=0.006) and decreased ED50 by 65% (p=0.0001) (Tables 3, 4 and Figure 1b).  193 
The interaction between these characteristics was simulated to create typical dose-response 194 
curves shown in Figure 2.  Healthy male subjects had the lowest cough responses, whereas 195 
female non-atopic asthmatics had the highest cough responses to capsaicin. 196 
Capsaicin cough responses are associated with cough frequency and asthma control 197 
Higher 24 hour cough frequency (coughs/hr) was associated with increased Emax (p=0.006) 198 
(Figure 3a, Table 3). Specifically, for every unit that cough frequency increased, Emax 199 
increases by approximately 5%. Also, higher ACQ scores were associated with lower ED50 200 
(p=0.02) (Figure 3b, Table 3). The median ACQ score in the studied asthmatic population 201 
was 0.71; if, for example, this score increased by one unit (1.71) ED50 decreased by 48%. 202 
Finally, higher IgE levels were associated with an increase in ED50 (p=0.01) (Figure 3c and 203 
Table 3). For every unit that IgE increased, ED50 increased approximately by 0.15%. The 204 
effect of these continuous covariates on the simulated dose response curves is illustrated in 205 
Figure 4. 206 
Other co-variates such as age, BMI, % FEV1 predicted, the PC20, FeNO, serum eosinophils 207 
and LCQ had no significant influence on model parameters (Emax, ED50, γ). There was a non-208 
significant trend (p=0.09) that asthmatics on steroids had a lower maximal number of 209 
coughs (Emax) compared with asthmatics not on steroids, but no differences were observed 210 
for ED50 or γ. In addition, the magnitude of steroid dose (in subjects on steroids) did not 211 
impact on the model parameters. 212 
Termination of the cough challenge 213 
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At higher doses of capsaicin, increasing numbers of patients elected to terminate the 214 
challenge (Figures E2 and E4a). The most important determinant of whether an individual 215 
was likely to terminate the challenge at a given dose level was the total cumulative number 216 
of coughs, up to the maximum tolerated dose (see Figure E4b). When subjects reached an 217 
approximate threshold of 40 to 60 cumulative coughs, they tended to terminate no matter 218 
whether this threshold was reached at a low or high capsaicin dose (see Figure E4b). 219 
Safety of full dose capsaicin challenge 220 
Transient bronchoconstriction after inhaling capsaicin has been reported in patients with 221 
asthma
18
. In this study there was no significant bronchoconstriction after inhaling high dose 222 
capsaicin; the median change in % FEV1 post capsaicin challenge was -1.7% (IQR 0.8 to - 223 
4.3). However, one subject did drop their FEV1 by 54% and coughed a total of 38 times at a 224 
low concentration of capsaicin (15.6μmol/L). The subject received 4 inhalation of salbutamol 225 
(100mcg) after which the FEV1 improved to baseline. 226 
Exploratory analysis of C2 and C5 endpoints 227 
Subjects with asthma demonstrated a significantly lower C2 and C5 than healthy controls 228 
(p=0.002 and p=0.013 respective, see Table E1). However, there was substantial variability 229 
between individuals and overlap between the two groups for C2and C5; 42% of healthy 230 
volunteers and 30% of subjects with asthma did not have a measureable C5 (see Figure E5). 231 
Furthermore, multiple linear regression models failed to show significant relationships 232 
between covariates which were identified as important in the non-linear model, only log 233 
ACQ was related to log C5 (see online repository for full details).  234 
 235 
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DISCUSSION 236 
This study is the first to show evidence of heightened capsaicin cough responses and thus 237 
neuronal dysfunction in stable, mild to moderate asthma. These changes in capsaicin 238 
responses can only be fully appreciated by extending cough challenge beyond the standard 239 
C5 endpoint and with the implementation of population pharmacodynamic modelling to 240 
provide individual estimates of ED50 and Emax. Using this methodology, we showed that 241 
compared with healthy volunteers, asthma patients started to cough at lower capsaicin 242 
doses (lower ED50) and had greater maximal cough responses (higher Emax), both indicative 243 
of increased excitability of the neuronal pathways controlling cough. Notably, both gender 244 
and atopic status significantly influenced cough responses, with non-atopic female asthma 245 
patients exhibiting the greatest degree of neuronal dysfunction. Importantly, measures of 246 
inflammation such as FeNO, bronchial hyper-responsiveness (BHR, PC20) or lung function did 247 
not influence Emax or ED50, suggesting this neuronal dysfunction was independent of airway 248 
inflammation and bronchial hyper-responsiveness. 249 
It is difficult to directly compare these results with other studies which have used the 250 
standard C5 endpoint, because the patient demographics are very different to those in our 251 
study. Doherty and colleagues compared C5 in a group of asthmatics and healthy volunteers 252 
and demonstrated an increased sensitivity to capsaicin
10
. However, subjects in that study 253 
were older with more severe asthma (mean FEV1 % predicted (71%), all on inhaled steroids, 254 
21% on an inhaled anti-cholinergic and 8% on theophylline), and only 43% were non-255 
smokers. Fujimura and colleagues evaluated just 18 asthmatics with worse lung function 256 
(mean %FEV1 predicted 67%) yet found no difference in C5 from healthy controls
19
. It was 257 
striking that we demonstrated highly statistically significant differences in capsaicin 258 
responses in a cohort of younger patients who were all non-smokers, with good lung 259 
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function and almost half were steroid naïve. Our exploratory analysis extrapolating C2 and 260 
C5 from our challenge protocol, shows these endpoints are statistically different in asthma 261 
compared with healthy volunteers. However, unlike Emax and ED50, C2 and C5 did not 262 
relate to any of the clinical features of asthma apart from control; not even with cough 263 
frequency which might be expected. This suggests C2 and C5 are not only less powerful that 264 
Emax and ED50 but also do not represent the underlying mechanisms important in different 265 
asthma phenotypes. 266 
Gender differences in evoked cough have not previously been specifically described in 267 
asthma but have been repeatedly shown in both healthy volunteers and chronic cough 268 
patients, with females demonstrating heightened responses compared with males
15, 20
. 269 
However, the observation that non-atopic asthma subjects have exaggerated responses 270 
(increased Emax) compared with atopic asthma is a novel finding that was unexpected and 271 
requires further exploration. Consistent with this, lower IgE was associated with reduced 272 
threshold for capsaicin evoked coughs (reduced ED50). The combined effects of gender and 273 
atopy suggest that the highest cough responses and thus, the greatest degree of neuronal 274 
dysfunction, was exhibited by female, non-atopic asthmatics. By comparison, atopic male 275 
asthmatics displayed the lowest levels of dysfunction in subjects with asthma and healthy 276 
male subjects the lowest responses overall (Figure 2). Our findings could help explain the 277 
results of a cluster analysis of asthmatics, highlighting two discordant groups where 278 
symptoms did not match the degree of airway inflammation
21
. Interestingly, excessive 279 
symptoms were observed in the predominantly female cluster with fewer atopics, whilst 280 
low symptoms were observed in the cluster who were predominantly male and atopic. 281 
Therefore we speculate that neuronal dysfunction could explain the discordance between 282 
such clinical phenotypes of asthma.  283 
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We also found capsaicin cough responses were relevant to the clinical manifestations of 284 
asthma. Poorer asthma control, as measured by ACQ scores, was associated with lower 285 
cough thresholds (ED50), and higher 24hr objective cough frequencies associated with higher 286 
maximal cough responses (Emax). It is interesting to speculate that these differences in 287 
capsaicin cough responses may represent different mechanisms of neuronal dysfunction, 288 
either in the peripheral or central nervous system. Moreover these changes in cough reflex 289 
responses may also provide a surrogate for changes in other populations of airway nerves 290 
responsible for mediating symptoms that are less easily quantified such as chest tightness 291 
and breathlessness. 292 
Nerve fibres have a maximum frequency of action potential firing, determined by the rate of 293 
membrane repolarisation (refractory period). However, the threshold for action potential 294 
generation can be lowered by changes in the membrane resting potential or ion channels at 295 
the nerve terminal e.g. increased expression, membrane insertion, and conformational 296 
changes
22
. Such changes can be induced by a range of inflammatory mediators including 297 
cytokines, chemokines and growth factors. Aδ fibres can also become responsive to 298 
capsaicin following airway exposure to allergen and cigarette smoke, with novel gene 299 
expression of TRPV1, known as phenotypic switching
23
. This can potentially affect both the 300 
ED50 and Emax; the membrane depolarisation threshold can be reached more easily causing a 301 
left shift (lower ED50) but in addition, the usual Emax ceiling can be exceeded by the 302 
recruitment of a newly capsaicin responsive nerve fibre sub-type. Whilst changes to the 303 
afferent fibres innervating the airways are the most plausible explanation for the 304 
exaggerated cough responses we have observed in asthma, modification of action potentials 305 
at the first synapse in the brainstem and in the cortical and sub-cortical pathways could also 306 
occur. Processes analogous to central sensitisation
24, 25
, and/or loss of descending neural 307 
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inhibitory control mechanisms, as described in chronic pain states, have the potential to 308 
produce similar effects
26
. However, these possible mechanisms are largely unexplored in 309 
asthma.  310 
As asthma is generally considered to be a chronic inflammatory disease, with the role of 311 
airway innervation or even the contribution of neuro-immune interactions rarely 312 
investigated. Cytokines, chemokines, growth factors and lipids released by immune cells 313 
have all been shown to induce profound changes in the activity and sensitivity of peripheral 314 
nerve terminals in the somatosensory system and have the potential to explain the changes 315 
in neuronal function that we have observed
27, 28
. In particular, growth factors e.g. nerve 316 
growth factor (NGF) and brain derived neurotrophic factor (BDNF) have the potential to 317 
induce long term qualitative changes to a range of stimuli to which nerves respond, and this 318 
has been demonstrated in an animal model of allergic asthma
23
. However, the most 319 
heightened neuronal dysfunction was observed in non-atopic asthma and perhaps therefore 320 
subjects with ‘low Th-2’ disease. Therefore perhaps neuronal dysfunction has the potential 321 
to provide insights into mechanisms underlying this phenotype and suggest new treatment 322 
targets. 323 
There are some limitations to this study. Firstly, the study population was young, mainly 324 
atopic, and predominantly steroid naïve. It is currently unclear how generalisable these 325 
findings are to other age groups with more severe disease. Secondly, apart from measuring 326 
serum eosinophils, IgE and FeNO, we did not make direct measures of airway inflammation 327 
and hence were not able to investigate whether these influenced capsaicin responses. 328 
Finally, we chose capsaicin as it is the most widely used cough challenge agent, and it is with 329 
this methodology that we developed the previous pharmacodynamic model
15
. However, it 330 
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remains to be seen whether other challenge agents, such as citric acid, provide different 331 
results and hence novel insights into cough mechanisms. 332 
In conclusion, these data are consistent with the concept that neuronal dysfunction is a 333 
feature of asthma, even in mild stable disease. Assessing capsaicin evoked cough responses 334 
may therefore provide an additional tool in phenotyping asthma and identifying those in 335 
whom this mechanism may be most prominent. Although our data suggests neuronal 336 
dysfunction seems to be independent of indirect measures of airway inflammation, studies 337 
are required to directly assess the effects of airway inflammation on capsaicin evoked 338 
coughs. If neuronal dysfunction is truly independent of airway inflammation it is unlikely to 339 
be addressed by current therapies. Hence, novel neuro-modulatory treatments may be a 340 
useful adjunct in treating asthma, and perhaps most effective in non-atopic patients. 341 
 342 
 343 
  344 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
ACKNOWLEDGMENTS 345 
The authors would like to thank all the subjects who participated in the study, and also, the 346 
National Institute for Health Research (NIHR) South Manchester Clinical Research Facility 347 
(CRF) and the NIHR/Wellcome Trust Central Manchester CRF.  348 
We would also like to thank Dr Elizabeth Juniper and Dr Surinder Birring who gave 349 
permission to use the ACQ and LCQ questionnaires respectively, and Dr Piet van der Graaf 350 
and Dr Paul Baverel, who first developed the modelling approach for capsaicin cough 351 
responses   352 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
TABLES AND FIGURES:  353 
Table 1: Comparison of subjects with asthma and healthy volunteers. Data quoted as 354 
median and interquartile range (IQR) and compared using the Mann Whitney U Test. 355 
 Asthmatics Healthy Volunteers (HV) P-value 
Participants (N) 97 47  
Age (Years) 23.0 (21.0-27.0) 38.0 (29.0-47.0) <0.001 
Gender (M:F) 39:58 17:30 0.64 
BMI (kg/m
2
) 24.1 (21.8-27.0) 25.0 (22.2-28.6) 0.25 
Smoking History (Pack Years) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.34 
FEV
1
 (%Predicted) 95 (87.0-103.0) 103.0 (97.0-115.0) <0.001 
FVC (%Predicted) 102 (95-110) 106.0 (99.0-118.0) 0.02 
Cough Frequency 
(c/h) 
24hr 1.1 (0.5-2.4) 0.2 (0.0-0.9) <0.001 
Day 1.6 (0.7-3.8) 0.2 (0.0-1.3) <0.001 
Night 0.0 (0.0-0.4) 0.0 (0.0-0.1) 
0.25 
 356 
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Table 2: Description of the key characteristics of patients with asthma. Data quoted as 358 
median (IQR) 359 
Characteristic 
All Asthmatics 
(n=97) 
Male  
(n=39) 
Female  
(n=58) 
Age 
23.0  
(21.0-27.0) 
23.0  
(21.0-25.0) 
22.0 
 (20.0-27.5) 
Age of Onset 
7.0  
(4.0-14.0) 
7.0  
(4.0-14.0) 
7.5  
(4.0-14.3) 
Exacerbations/year 0(0-0) 0(0-0) 0(0-0) 
ACQ Score 
0.71  
(0.43-1.00) 
0.86  
(0.50-1.21) 
0.64 
 (0.43-1.00) 
Smoker 
No (%) 91.8 89.7 93.1 
Ex (%) 8.2 10.3 6.9 
Yes (%) 0 0 0 
GINA Category 
Well Controlled (%) 50.5 56.4 46.6 
Partly Controlled (%) 49.5 43.6 53.4 
Steroid Naïve (%) 48.5 43.6 43.1 
On ICS alone (%) 34.0 23.1 41.4 
On ICS/LABA combination (%) 17.5 20.5 15.5 
Daily ICS Dose (mcg FP equivalent) 
200  
(100-400) 
200  
(100-400) 
200  
(100-400) 
Reversible volume (mls) 
180  
(75-275) 
260  
(160-420) 
135  
(48-230) 
Proportion with significant reversibility 
≥12% (%) 
14.4 17.9 12.1 
FeNO (ppb) 
34  
(21-75) 
37 
(23-91) 
30 
(21-54) 
Methacholine PC20 mg/ml 
0.94  
(0.25-3.26) 
1.62  
(0.46-3.21) 
0.86  
(0.24-3.40) 
Bronchial Hyper-reactivity (%) ≤8mg/ml 81.4 79.5 82.8 
Peak Flow Variability (%) 
5.4  
(3.4-6.9) 
5.7  
(4.2-7.7) 
5.2  
(3.2-6.8) 
Atopic* (%) 78.4 87.2 72.4 
Serum eosinophils (x10^9/L) 
0.21  
(0.13-0.35) 
0.25 
 (0.13-0.41) 
0.21  
(0.13-0.32) 
Serum total IgE (ku/L) 200  210 175  
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(58-470)  (70.0-460) (41-483) 
* At least one positive skin prick test to common aero-allergen. See online repository for full 360 
list. 361 
  362 
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Table 3: Parameter estimates of the final population pharmacodynamic model. θ1-5 363 
describe the model parameters for a healthy male with the typical (median) population 364 
values for each model incorporated covariate. θ6-13 describe the influence of each covariate 365 
on the model parameters Emax and ED50 (see Eqs.E5, E6 in online repository). For example, 366 
the presence of asthma lowers ED50 by 71% (θ6). η1-3 refer to the inter-individual variability 367 
with regard to Emax, ED50 and γ (slope). 368 
γ:Hill factor (slope);  K: tachyphylaxis parameter; E0: average cough response at baseline; 369 
RSE%: relative standard error %. 370 
Model parameter NONMEM estimate 
(RSE%)
 
Bootstrap estimate  
(95% CIs)
 a 
Structural model   
θ1: Emax 3.57 (10) 3.59 (2.93, 4.52) 
θ2: ED50 67.6 (33) 68.8 (35.0, 135.9) 
θ3: γ 2.11 (5) 2.13 (1.89, 2.55) 
θ4: E0 0.063 (23) 0.062 (0.041, 0.091) 
θ5: K 0.142 (10) 0.143 (0.115, 0.173) 
Covariate effects 
b 
  
θ6: Asthma on ED50 -0.71 (13) -0.704 (-0.842, -0.462) 
θ7: Female on ED50 -0.647 (15) -0.654 (-0.807, -0.412) 
θ8: Asthma (non-atopic) on Emax 0.462 (37) 0.448 (0.156, 0.870) 
θ9: Female on Emax 0.269 (39) 0.250 (0.043, 0.494) 
θ10: Atopy on Emax -0.209 (35) -0.204 (-0.353, -0.033) 
θ11: Cough frequency on Emax 0.0482 (29) 0.0482 (0.0137, 0.0807) 
θ12: ACQ on ED50 -0.66 (39) -0.69 (-1.28, -0.17) 
θ13: IgE on ED50 0.00145 (49) 0.0014 (0.0002, 0.0029) 
Inter-individual variability (%CV)
c
   
η1: Emax 40.1 (8) 38.0 (29.0, 47.2) 
η2: ED50 281.7 (10) 272.3 (172.9, 446.1) 
η3: γ 36.8 (13) 39.0 (23.8, 55.1) 
a
 Estimates obtained from bootstrap with the final population model. The median of the 371 
bootstrap sample estimates together with the non-parametric 95% confidence intervals 372 
(CIs) are reported for each parameter. 373 
b
 The increase in objective function (-2log-likelihood) after removing each covariate effect 374 
from the final model is listed below followed by the corresponding likelihood ratio test p-375 
value in parenthesis. θ6: 11.25 (p=0.0008);  θ7: 14.43 (p=0.0001);  θ8: 8.55 (p=0.003);  θ9: 376 
7.47 (p=0.006);  θ10: 4.24 (p=0.04);  θ11: 7.40 (p=0.006);  θ12: 5.21 (p=0.02);  θ13: 6.58 377 
(p=0.01) 378 
c
 Coefficient of variation (% CV) is calculated as:  ( − 1) ∙ 100 379 
 380 
  381 
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Table 4: Emax and ED50 values for healthy volunteers and asthmatics Values below 382 
represent the Emax and ED50 values for a typical healthy and asthmatic male/female (i.e. with 383 
median values for all model-incorporated covariates). 384 
 385 
 
Healthy volunteer 
Asthmatic 
Atopic Non-atopic 
 Male Female Male Female Male Female 
Emax 3.57  4.53 4.13 5.24 5.22   6.62 
ED50 67.6  23.86 19.6 6.92 19.6  6.92 
  386 
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FIGURE LEGENDS: 387 
Figure 1: Model fit to the observed dose-response data stratified by significant categorical 388 
covariates; (a) healthy volunteers vs asthmatics, (b) males vs females, (c) atopic vs non-389 
atopic asthmatics. The average number of coughs (y-axis) is plotted against the capsaicin 390 
dose (x-axis). Bars and red lines represent the observed and model-predicted respectively 391 
number of coughs averaged across all individuals in a specific covariate subpopulation and 392 
all inhalations at a given capsaicin dose level. The number of individuals in each 393 
subpopulation subjected to at least one inhalation at a given dose level are also reported 394 
inside (or above) each bar. 395 
Figure 2: Model-simulated typical dose-response curves for individuals with different 396 
population characteristics. The typical (median) population values have been assumed for 397 
the model-incorporated continuous covariates; NA: non-atopic, A: atopic 398 
Figure 3: Model fit to the observed dose-response data stratified by significant continuous 399 
covariates. Subpopulations are stratified in relation to the median population value of each 400 
covariate; (a) low vs high cough frequency (in coughs/h), (b) low vs high ACQ score, (c) low 401 
vs high IgE levels (ku/L). The average number of coughs (y-axis) is plotted against the 402 
capsaicin dose (x-axis). Bars and red lines represent the observed and model-predicted 403 
respectively number of coughs averaged across all individuals in a specific covariate 404 
subpopulation and all inhalations at a given capsaicin dose level. The number of individuals 405 
in each subpopulation subjected to at least one inhalation at a given dose level are also 406 
reported inside (or above) each bar. 407 
 408 
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Figure 4: Effect of the model-incorporated continuous co-variates on the simulated dose-409 
response curves; (a) cough frequency (Cfreq, coughs/h) (b) ACQ score, and (c) serum IgE 410 
levels (ku/L). Model simulated dose-response curves show the influence of continuous 411 
covariates at 3 incremental values (5th, 50th and 95th percentile in the analysed dataset) 412 
using an atopic asthmatic male as an example reference. The typical (median) population 413 
values have been assumed each time for the remaining continuous co-variates. 414 
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METHODS:  
Procedural Details 
Fraction of Exhaled Nitric Oxide: Exhaled nitric oxide (eNO) was measured at a rate of 
50ml/sec (NIOX, Aerocrine) prior to spirometry.  
Spirometry: Spirometry was performed (In2itive, Vitalograph) according to standard 
American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines. Volume 
(ml) and percentage reversibility was assessed after administering 400mcg of salbutamol 
using a volumatic spacer device.  
Questionnaires: Subjects completed the full Asthma Control Questionnaire (ACQ) and 
Leicester Cough Questionnaire (LCQ) described previously. Subjects were also classified on 
the basis of GINA categories; well controlled, partly controlled, not well controlled. The 
latter group were excluded from the study. 
Cough Monitoring: Objective 24 hour cough monitoring was performed using the VitaloJAK 
cough recorder (Vitalojak; Vitalograph Ltd, Buckinghamshire, UK). Twenty-four hour 
ambulatory cough sound recordings were performed using a custom-built validated 
recording device and microphone. Briefly, this consists of a digital data logger recording 
sounds at a sample rate of 8 kHz, 16-bit resolution and in wav format, which is a commonly 
used uncompressed sound file format. Recordings were transferred to a personal computer; 
silences and background noise removed by validated, custom-written software (1); and 
cough sounds counted using an audio editing package (Audition version 3; Adobe Systems 
Inc., San Jose, CA) and the number of coughs expressed as coughs per hour (c/h). 
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Blood Sampling: Two samples of blood tests were taken from subjects with asthma for full 
blood count (to assess serum eosinophils) and total IgE.  
Skin Prick Testing: Atopy was defined by the presence of at least one positive skin prick test 
(≥3mm) to commonly inhaled aeroallergens. The following were tested: 
1. House Duse Mite  
2. Mixed Moulds I: Alternaria tenuis, Botrytis cinerea, Cladosporium herbarum, Curvularia 
lunata, Fusarium moniliforme, Helminthosporium halodes 
3. Mixed Moulds II: Aspergillus fumigatus, Mucor mucedo, Penicillium notatum, Pullularia 
pullulans, Rhizopus Nigricans, Serpula lacrymans 
4. Grass Mix: yorkshire fog/velvet grass, cocksfoot, rye grass, timothy, meadow 
grass/kentucky blue grass, tall fescue/meadow fescue  
5. Tree Mix (Mid Blossoming): birch, beech, oak, plane 
6. Cat 
7. Dog 
8. Histamine (positive control) 
9. Saline (negative control) 
Bronchial Hyper-responsiveness Testing: Methacholine challenge was performed to assess 
bronchial hyper-responsiveness using the 2-minute tidal breathing methodology according 
to standard ATS guidelines. Subjects were withdrawn off any inhaled medications as per ATS 
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guidelines (2). The concentration causing a 20% drop from baseline FEV1 in response 
methacholine (PC20) was documented.  
Capsaicin Cough Challenge: Full dose capsaicin evoked cough challenge was performed 
using the methodology described  previously (3) using a nebuliser pot (Model 646; Devilbiss 
Healthcare LLC) and dosimeter (Koko Dosimeter; Ferraris Ltd, Hertford, United Kingdom). 
Two millilitres (ml) of Capsaicin solution at 1000 µmol/L (Stockport Pharmaceuticals, 
Stockport, UK) was serially diluted with 2 ml saline (0.9%) to create solutions of 
concentrations 500, 250, 125, 62.5, 31.3, 15.6, 7.8, 3.95, 1.95, 0.98 and 0.48 µmol/L. 
Spirometry was performed and a cough monitor (VitaloJAK) attached to aid in the manual 
verification of capsaicin evoked coughs later on. To ensure accurate dosing was achieved, 
calibrated devilbiss 646 nebuliser pots were fitted with an inspiratory flow limiter and 
connected to a dosimeter (KoKo) at a pressure of 30 psi. This emitted between 10-12 μL per 
actuation. The full dose capsaicin evoked cough challenge involved administering four 
inhalations, thirty seconds apart, of doubling doses of capsaicin, starting from 0.48 to 1000 
µmol/L. After each inhalation, the number of coughs in the first 15 seconds were recorded 
and later verified. The highest total number of coughs evoked at any dose of capsaicin is 
denoted Emax and the dose evoking half this response ED50. To explore how these novel 
endpoints compare with traditional cough challenge endpoints, we also calculated the 
concentration of capsaicin evoking atleast 2 and 5 coughs, i.e. the C2 and C5. Our challenge 
methodology is slightly different from the traditional challenge as four rather than one 
inhalation are performed at each concentration. Therefore, to calculate the C2 and C5 we 
simply used the number coughs evoked by the first of these four inhalations. If subjects did 
not cough 2 or 5 times during the whole challenge then for the purposes of analysis a value 
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of 2000µmol/L was assigned. Spirometry was performed after the challenge and if there was 
more than a 10% drop in FEV1 compared to baseline or subjects complained of any chest 
symptoms then 4 puffs of salbutamol (100mcg) via a spacer was administered. The 
challenge ended when the patient reached the final concentration of capsaicin or reached 
the maximal tolerated dose. 
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Non-linear mixed effects modelling in detail 
Population pharmacodynamic model 
Model structure 
Population pharmacodynamic modelling was performed using nonlinear mixed effects 
modelling software NONMEM version 7.3 (ICON Development Solutions) and the Laplace 
estimation method (4, 5). Goodness-of-fit plots, statistical analysis and simulations were 
performed in Matlab R2014a (The MathWorks, Inc.). In total 6606 observations (verified 
cough measurements) from 144 individuals were analysed for the development of the 
population dose-response model. The response variable (number of coughs) is discrete 
(count data) and was assumed to follow the Poisson distribution (6) (Eq.E1). 
 =  =
	
 ∙ 

!
									.  
, where 	 =  is the probability that individual 	 is having 	= 0,1,2, …  number of 
coughs per interval of time and  is the individual mean count response. The individual 
mean count response () is expressed as a function of capsaicin dose according to Eq.E2. 
 =  +
  ∙ !"
!50
" + !"
									. $ 
, where  represents the mean cough count at baseline (placebo),   	is the maximum 
number of coughs in individual 	, !50  is the capsaicin dose that induces half of the 
maximum effect in individual 	, 	! is the administered capsaicin dose and % is the Hill factor 
that controls the steepness of the dose-response sigmoidal curve in individual 	. 
Inter-individual variability random effect terms were assigned on model parameters 
(	 , !50, %) using an exponential relationship (Eq.E3). 
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  = &'()* ∙ +,-./ 									. 0  
, where &'()*  is the typical 	  parameter value in the population and 1'()* is the 
	  inter-individual variability random effect parameter which is assumed to be normally 
distributed with mean zero and variance, 2'()*3 . 
Tachyphylaxis effect 
In a previous study (3) it was identified that the incorporation of a tachyphylaxis parameter 
substantially improved the description of the observed cough response data after serial 
capsaicin inhalations. Therefore in the current work, we carefully examined the data with 
regard to the occurrence of a tachyphylaxis pattern between consecutive inhalations of the 
same capsaicin dose. In the case that such a pattern was apparent we subsequently 
incorporated a tachyphylaxis parameter (	4) in the model (similarly to (3)) according to 
Eq.E4 and investigated the extent that model fit was improved. 
 5 + 1 =  5 ∙ 	6									. 7 
, where 	5 =1,2,3;  5		and  5 + 1	correspond to the individual 	  
referring to the  jth and  j+1th inhalation respectively of the same capsaicin dose; and 	4 is a 
positive real number. The equation above implies that tachyphylaxis (reduced response) 
occurs between consecutive inhalations of the same capsaicin dose.  
Covariate model building 
After the development of the base population pharmacodynamic model, a covariate 
analysis was performed in an effort to explain some of the observed inter-individual 
variability in cough responses. Both continuous and categorical covariates were investigated 
in the covariate model building procedure including: age, gender, body mass index, disease 
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state (health or asthma), atopy (atopic or non-atopic), predicted FEV1, cough frequency 
(Cfreq) from the monitoring of spontaneous cough, IgE levels, eosinophil levels, FeNO levels 
and ACQ, LCQ questionnaire scores. Empirical Bayes estimates of the inter-individual 
variability random effects (1) from the base model (without any covariates) were used for 
an initial screening of the covariates, given a low 	1 -shrinkage (7). Subsequently covariate 
model building was performed with a stepwise forward inclusion – backwards deletion 
procedure where covariate selection is guided at each step by likelihood ratio tests between 
nested models (8, 9). A bootstrapping procedure (n=1,000) was performed with PsN 3.7.6 
(Perl-speaks-NONMEM) (10) for the final model in order to evaluate the robustness of the 
parameter estimates and provide non-parametric 95% confidence intervals. A covariate 
effect was retained in the final model only if all the following conditions applied: i) the 
direction of the covariate effect was physiologically / mechanistically plausible based on our 
understanding of the underlying system and prior knowledge; ii) removal of the covariate 
caused the model to be inferior at the 0.05 statistical level (assessed by likelihood ratio 
test); iii) the bootstrap-obtained non-parametric 95% confidence interval for the covariate 
effect did not include zero. 
Investigation of termination of the cough challenge 
Due to the nature of the ascending-dose capsaicin challenge it is expected that a substantial 
number of participants will elect to terminate the challenge before reaching the maximum 
capsaicin dose. Possible reasons for terminating the challenge include discomfort due to 
excessive coughing or sensations of heat/stinging/burning in the throat at higher 
concentrations of capsaicin. Termination of the cough challenge results in missing data at 
higher capsaicin concentrations which may have implications for the modelling strategy / 
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methodology. Therefore, an exploratory statistical and graphical analysis of the raw cough 
response data was performed to further understand the reasons for termination of the 
cough challenge. 
Linear regression modelling of C2 and C5 
In order to explore the utility of C2 and C5, we compared log base 10 transformed values in 
health and disease using an independent t-test. To see how these endpoints performed 
compared with Emax and ED50, we carried out linear regression modelling to test whether 
the features of asthma found to influence Emax and ED50 similarly influenced logC2 and 
logC5. 
RESULTS 
Detailed Results of Modelling 
Population pharmacodynamic model  
The parameter estimation process and the covariance step for the final population 
pharmacodynamic model (including covariates) converged successfully under the Laplace 
estimation method and a requested precision of more than three significant digits in the 
parameter estimates. The parameter estimates of the final population model are reported 
in Table 3 (main manuscript), together with the bootstrap results and the 95% non-
parametric confidence intervals around these estimates. All model parameters (including 
both fixed and random effects) were estimated with adequate precision (see Table 3 in main 
manuscript). The average cough response at baseline, referred as , was estimated to be 
only 0.06 indicating that cough response is very rare when the capsaicin dose is zero. 
Tachyphylaxis effect 
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A tachyphylaxis pattern was apparent after examination of the raw cough response data, as 
the magnitude of response (number of coughs) was decreased with consecutive inhalations 
of the same capsaicin dose. Similar to the tachyphylaxis pattern previously reported (3), this 
was apparent in all the capsaicin dose levels  apart from the two low doses (0.48, 0.98µM) 
where cough responses were minimal and the highest dose (1000µM) where the sample 
size was small as many subjects had terminated the challenge before this dose. 
Incorporation of a tachyphylaxis parameter (	4), substantially improved the model fit and 
model diagnostics and was retained in the final model. More specifically incorporation of 
this parameter in the model decreased the objective function value (-2log-likelihood) by 181 
units. The tachyphylaxis parameter (	4) was estimated to be 0.142 (see Table 3 in main 
manuscript), which practically means that the 	  decreases approximately by 13% 
(calculated as 1 − 	6 = 0.13) for any capsaicin inhalation preceded by another inhalation 
at the same dose level, in agreement with our previous work where using another 
population the decrease in 	  due to tachyphylaxis was estimated to be around 15% 
(3). This replication provides additional confidence that the model adequately captures the 
true quantitative effect of the underlying tachyphylaxis physiological mechanism on the 
observed cough response. 
Inter-individual variability random effect terms were assigned on the following structural 
model parameters: 	 , !50 and %. The estimates of these variability terms (see Table 
3 in main manuscript) clearly indicated that the magnitude of population variability in 
	!50 was vast (CV (coefficient of variation) of 282%) and in particular, higher than the 
population variability in 	  (CV of 40%). The magnitude of 	1 -shrinkage in the final 
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population model was 19%, 3% and 32% for the inter-individual variability terms of 	 , 
!50 and % respectively. 
The observed raw dose-response data together with the model fit are illustrated in Figure 
E2, where it is apparent that the developed model provided a very good fit to the observed 
data. The pattern of decreased average number of coughs observed in the last few high 
doses of capsaicin did not represent a true dose-response relationship, but was due to the 
subset of individuals that reached these high dose levels having substantially lower 	  
and higher 	!50 values i.e. they had overall reduced cough responses to capsaicin.  
The model fit to the observed dose-response data at the individual level is illustrated in 
Figure E3 for 16 representative subjects. It is clearly demonstrated that observed dose-
response relationship is completely different between individuals. For example, some 
subjects had a substantial number of coughs relatively early in the ascending dose challenge 
(e.g. ID=6), whilst others had only a limited number of coughs even in the highest dose 
levels (e.g. ID=31, ID=300). However, it is apparent from Figure E3, that the developed 
mixed-effects population model is flexible enough to very accurately capture all these 
patterns of different dose-response relationships across different individuals. 
Identification of covariate effects 
The final population model included the influences of both categorical and continuous 
covariates: disease state (health or asthma), gender, atopy (atopic or non-atopic), cough 
frequency (Cfreq), ACQ questionnaire score and IgE levels. The inclusion of these covariates 
resulted in a substantial improvement of the model as they decreased the objective 
function (-2log-likelihood) by approximately 68 units compared to the objective function of 
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the base model (model with no covariates). All the covariates retained in the final model 
offered additional and at least partly unique information, as removal of each of the 
covariates causes the model to be statistically inferior. The level of statistical evidence 
regarding each covariate (increase in objective function after removing each covariate from 
the final model and the corresponding likelihood ratio test p-value) is presented in the 
legend of Table 3 (main manuscript). In addition the bootstrap-obtained non-parametric 
95% confidence intervals regarding all the covariate effects in the final model are reported 
in Table 3 (main manuscript) where it is apparent that they do not include zero. The 
equations that described the typical values of the model parameters including covariate 
effects are listed below: 
 = &: ∙ 1 + ;<=> ∙ &? ∙ 1 + ;@ ∙ &A ∙ 1 + ;<=> ∙ BC= ∙ &: ∙ DEE∙
FGHIJ	.KL							. M 
!50 = &3 ∙ 1 + ;<=> ∙ &N ∙ 1 + ;@ ∙ &K ∙ O1 + ;<=> ∙ &:P ∙ QR − 200S ∙ TUVW∙DEX∙
YFZ	.K:						. [ 
, where 	;<=> is a dummy variable that takes the value 1 for asthmatics and 0 for healthy 
volunteers; 	;@ is a dummy variable that takes the value 1 for females and 0 for males; 
	BC= is a dummy variable that takes the value 1 for atopic asthmatics and 0 for non-atopic 
asthmatics; \]^_ is the spontaneous cough frequency (coughs/h) over 24hrs; 	QR is the 
IgE levels measurement (ku/L); and 	B\` is the ACQ questionnaire score. 
For all continuous covariates in the model (\]^_, 	QR and 	B\`), covariate effects were 
centred around the median population values in the analysed dataset (0.75, 200 and 0.71 
respectively) to increase model stability and allow parameter interpretation with respect to 
a typical/reference individual. It should be noted that \]^_ values were missing for 7 out 
of the 144 studied individuals, so these values were imputed with the population median. 
This imputation did not have an impact on the results, as when these individuals were 
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excluded from the analysis all the parameter estimates (including all covariate effects) were 
comparable. 
Figures 1 and 3 (main manuscript) illustrate the model fit to the observed dose-response 
data stratified by the significant categorical and continuous respectively model covariates. It 
is apparent from these figures that substantially different dose-response patterns were 
observed across the different covariate subpopulations (e.g. healthy volunteers vs asthma, 
males vs females etc.). However the developed covariate-incorporated population model 
very accurately described the observed dose-response relationships within each of these 
subpopulations. 
Model-simulated typical dose-response curves for individuals with different population 
characteristics are presented in Figure 2 (main manuscript), to illustrate the effect of the 
model-incorporated categorical covariates on the dose-response relationship. Similarly, the 
effect of the model-incorporated continuous covariates on the simulated dose-response 
curves is illustrated in Figure 4 (main manuscript).  
All the significant covariate effects (see Table 3 and Figures 1-4) are described in the main 
manuscript. It should be noted that although it was possible in the current work to explain 
part of the observed variability in cough response through the incorporation of several 
covariates, the extent of unexplained inter-individual variability remains substantial.  
Investigation of termination of the cough challenge 
An exploratory analysis of the raw cough response data with regard to termination of the 
challenge is illustrated in Figure E4. The number of individuals that performed at least one 
inhalation at a given dose level decreased as the capsaicin dose increased (Figure E4a). The 
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most important determinant of termination of the challenge at a given dose level, was the 
total number of coughs in the entire challenge up to that specific dose. Figure E4b shows 
that individuals who terminated the challenge at a given dose level had substantially more 
coughs in the challenge up to this dose compared with individuals who continued to the 
next capsaicin dose level; bootstrap 95% confidence intervals (using bootci in MATLAB) 
indicated a statistically significant difference in the number of coughs for the majority of the 
capsaicin dose levels. Figure E4b suggests that when individuals reach a threshold of 
approximately 40 to 60 coughs, they tend to terminate the challenge, irrespective of the 
dose of capsaicin at which this occurs. 
Although the missing data mechanism (termination of the challenge) was not independent 
of the response values, it depends on them only through the observed components of the 
response (number of coughs up the point of drop-out). Therefore, valid estimation-based 
inferences could be obtained with the maximum likelihood mixed effects modelling 
approach, without the need to simultaneously develop a model for the missing data (11). 
The development of a drop-out model for the capsaicin cough challenge, although not 
necessary for the analysis of this data set represents a significant task.  This is currently in 
progress as it will inform the design of future clinical studies and will allow the performance 
of clinical trial simulation.  
Exploratory analysis of C2 and C5 endpoints 
Comparison of healthy volunteers and asthmatics 
As illustrated by Table E1, asthmatics demonstrated a significantly lower C2 and C5, i.e. 
were more sensitive to capsaicin, than healthy volunteers. However, as shown in Figure E5, 
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there was substantial variability in these endpoints and overlap between health and disease. 
Moreover, many individuals in both groups did not achieve a measureable C5. particularly 
for the C5 endpoint (42% of healthy volunteers and 30% of asthmatics).  
Predictors of C2 responses  
Analysing healthy volunteers and asthma data combined in the simplest model, both gender 
(p<0.001) and disease group (p<0.001) significantly predicted log C2, explaining 17.5% of the 
variance; females were more sensitive to capsaicin than males and asthmatics more 
sensitive than healthy volunteers. However, when the predictors of capsaicin responses 
found to be significant in our non-linear modelling approach (disease group, gender, atopic 
status, log cough frequency, log total IgE, log ACQ) were introduced in the linear regression 
model, none significantly predicted logC2. 
Predictors of C5 responses  
Again in the simplest model, both gender (p=0.002) and disease group (p=0.002) 
significantly predicted log C5, explaining 11.2% of the variance. When the predictors of 
capsaicin responses found to be significant in our non-linear modelling approach were 
introduced in the linear regression model, only log ACQ significantly predicted logC5 (Beta=-
0.8, p=0.012), i.e. worse asthma control was associated with a lower C5. 
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TABLES 
Table E1 
 Group Geometric Mean, (95% CI) Capsaicin μmol/L p-value 
C2 Healthy Volunteers (n=47) 22.6 (12.1-42.1) 0.002 
Asthmatics(n=97) 7.3 (5.4-9.8) 
C5 Healthy Volunteers (n=47) 209.5 (108.5-404.5) 0.013 
Asthmatics(n=97) 78.2 (48.8-125.1) 
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FIGURE LEGENDS 
Figure E1: Patient flow diagram illustrating number of patients screened, withdrawals and 
missing data. 
Figure E2: Model fit to the observed dose-response data. The average number of coughs (y-
axis) is plotted against the capsaicin dose (x-axis). Bars and red line represent the observed 
and model-predicted respectively number of coughs averaged across all individuals and 
inhalations at a given capsaicin dose level. The number of individuals subjected to at least 
one inhalation at a given dose level are also reported inside (or above) each bar. 
Figure E3: Model fit to the observed dose-response data at the individual level. Observed 
data (bars) and individual model predictions (red lines) of 16 representative of the 
population subjects are presented. The number of coughs (y-axis) averaged across all 
inhalations at a given capsaicin dose level for a given individual is plotted against the 
capsaicin dose (x-axis). 
Figure E4: Investigation of the challenge termination pattern in the raw cough response 
data. (a): The number of individuals (y-axis) performing at least one inhalation at a given 
dose level is plotted against the capsaicin dose (x-axis); (b): average number of total coughs 
in the challenge (y-axis) up to a given capsaicin dose (x-axis) for individuals that do or do not 
terminate the challenge after this specific dose. For example the 4 individuals that dropped-
out after inhaling the 7.81 μmol/L dose (3rd marker from the left) had on average 43 coughs 
up to this point of the challenge; the 137 individuals that did not drop-out and continued to 
the higher dose level had on average only 13 coughs up to this point of the challenge. 
Markers highlighted with a star indicate a statistically significant difference in total coughs 
between the drop-out and the non-drop-out groups at the given dose level. 
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Figure E5: Comparison of traditional capsaicin challenge endpoints C2 (A) and C5 (B). Note 
logarithmic scale (base 10) of y axis and error bars show geometric mean and 95% 
confidence intervals. Dashed reference lines at 2000 µmol/L capsaicin represent  value 
assigned to those subjects who did not achieve C2 or C5.
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